Adjusted tight control blood glucose management in diabetic patients undergoing on pump coronary artery bypass graft. A randomized clinical trial

Abstract

Background Many of the patients who are undergoing Coronary Artery Bypass Graft have diabetes mellitus or metabolic syndrome and are at risk for hyperglycemia events.Objective The present study aimed to compare conventional glucose control with adjusted tight control in patients undergoing on-pump CABG. Methods This double -blind randomized clinical trial study was conducted in Shiraz, Iran, from September 2017-March 2018. Two consecutive groups of 75 patients undergoing elective on-pump coronary artery bypass graft surgery. Intervention The patients were divided into adjusted tight control of the blood glucose between 100 and 120 mg/dl and conventional method that the blood glucose maintained ≤200 mg/dl. Primary outcomes were mortality, sternal wound infection, cardiac arrhythmia, cerebrovascular attack, and acute renal failure. Secondary outcomes included duration of mechanical ventilation and length of ICU staying. The same main outcomes were evaluated after one month. Statistical analysis The data were analyzed using SPSS version 20(SPSS, Chicago, IL). Group comparisons were performed using t-tests and Chi-square tests. Repeated measurement test was used for comparing blood glucose in two groups. Mann Whitney U test was compared duration of the mechanical ventilation and length of ICU staying. Statistical significance was defined as a p value <0.05. Results There were no significant differences between main and secondary outcomes. About late outcomes, sternal wound infection was in the control group (7 patients) more than intervention (1 patient) (P < 0.05). No differences between other complications in both groups were observed. The occurrence of hypoglycemia was low in both groups. Hypokalemia was significantly higher in the intervention than in control (P < 0.001). Conclusions The findings showed using adjusted tight glycemic control to a level that is nearby to normal values during cardiac surgery may reduce episodes of hypoglycemia and thus reduces its side effects. As well as reduce hyperglycemic complications such as sternal wound infection.Trial registration number IRCT2013041713052N1). 2013-07-09. Keywords Cardiac surgery . Diabetes . Tight control of glucose . Critically ill patient Abbreviations CABG Coronary Artery Bypass Graft CVA cerebrovascular accident TIA transient ischemic attacks MDAS Memorial Delirium Assessment Scale BS Blood glucose AF Atrial Fibrillation The article 'Adjusted tight control blood glucose management in diabetic patients undergoing on pump coronary artery bypass graft. A randomized clinical trial', written by Fatemeh Javaherforoosh zadeh and Simin Azemati, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 20th

Strategies for post–cardiac surgery acute kidney injury prevention: A network meta-analysis of randomized controlled trials

“…The GLUCO-CABG trial compared intensive sugar control (100–140 mg/dL) with regular sugar control (141–180 mg/dL) and revealed no significant difference in perioperative complications between the two strategies ( 212 ). Two of the studies included in our analysis defined the intensive sugar control level as 80–110 and 100–120 mg/dL, respectively ( 121 , 178 ). Because the results of our NMA revealed that intensive sugar control is ineffective in preventing post–cardiac surgery AKI and is potentially associated with a higher risk of hypoglycemia and mortality, we argue that intensive sugar control should be applied with caution.…”

Lung injury after cardiopulmonary bypass: Alternative treatment prospects

“…These may limit the use of intralipid on-pump CABG. However, Javaherforoosh Zadeh et al [ 66 ] showed that using adjusted tight glycemic control to a level that is near to normal during cardiac surgery may reduce hyperglycemic complications. Due to the lack of research on proper intravenous dosage of intralipid in lung injury after CPB, more data are needed to confirm the specific dose to be used.…”

Effects of glargine on hyperglycemia in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft: A randomized, controlled, double-blind clinical trial

“…Studies estimated a prevalence of 30-40% for diabetes mellitus in patients undergoing coronary artery bypass grafting (CABG). 2 , 3 Diabetic patients undergoing CABG have a higher risk of postoperative morbidity and mortality, stroke, renal failure, infections, recurrent episodes of angina and readmission for cardiac-related issues or other causes. So that, increases in blood glucose levels before, during and immediately after surgery predict elevated perioperative complications in patients undergoing cardiovascular surgery; therefore, hyperglycemia is regarded as an indicator of poor outcomes among these patients.…”